Portal de Periódicos da CAPES

IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection

2021; Springer Science+Business Media; Volume: 49; Issue: 5 Linguagem: Inglês

10.1007/s15010-021-01651-4

1439-0973

Hari Ram Choudhary, Debaprasad Parai, Girish Chandra Dash, Annalisha Peter, Subrat Kumar Sahoo, Matrujyoti Pattnaik, Usha Kiran Rout, Rashmi Ranjan Nanda, Sanghamitra Pati, Debdutta Bhattacharya,

COVID-19 Clinical Research Studies

Coronavirus disease-19 (COVID-19) pandemic became the greatest public health challenge globally. Study of dynamicity and durability of naturally developed antibodies against SARS-CoV-2 are of great importance from an epidemiological viewpoint. In this observational cohort study, we have followed up the 76 individuals who tested positive for SARS-CoV-2 infection by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) for 16 weeks (post-enrolment) to record the periodic changes in titre, concentration, clinical growth and persistence of naturally developed SARS-CoV-2 antibodies. We collected serum samples from these individuals for 16 weeks with a frequency of weekly and fortnightly during each follow-up and tested them in two CLIA-based platforms (Abbott Architect i1000SR and Roche Cobas e411) for testing SARS-CoV-2 antibodies both qualitatively and quantitatively. We recorded the antibody magnitude of these individuals 10 times between September 2020 and February 2021. We found a waning of antibodies against nucleocapsid antigen protein but not a complete disappearance by the end of 16 weeks. Out of 76 cases, 30 cases (39.47%) became seronegative in qualitative assay, although all the sera samples (100%) remained positive when tested in quantitative assay. The lower persistence of anti-nucleocapsid SARS-CoV-2 antibody may not be the exact phenomenon as those cases were still seropositive against spike protein and help in neutralising the virus.